Recent pipeline updates have kept Biopharmaceuticals sentiment highly mixed. Positive oncology, renal, and rare-disease readouts, continued GLP-1 development, and a busy slate of regulatory catalysts are supporting momentum, while high-profile trial failures at AstraZeneca, AbbVie, and Novo Nordisk have reinforced the sector’s binary pipeline risk. The key question is whether upcoming approvals and late-stage readouts can offset patent-expiry pressure, rising R&D costs, and growing competition across major franchises.

This score is a snapshot of the season that just wrapped. It will hold steady until the new season begins in mid-October, at which point the index will refresh once 7 of the 13 companies have reported.